Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Long-Term Monitoring and Living with CIDP

At a Glance

Living with CIDP requires active long-term monitoring using objective tools like the I-RODS scale and hand-grip tests. While medications stop the immune attack, physical therapy is essential to rebuild muscle strength and maximize your long-term mobility and function.

Managing CIDP is a marathon, not a sprint. Once you and your medical team have found an effective treatment, the focus shifts from “stopping the fire” to long-term monitoring, maintaining your quality of life, and finding your “new normal” [1][2].

The Long-Term Outlook

While some patients may achieve long-term remission, CIDP is generally a chronic condition [1]. For many, the goal is finding a stable, long-term maintenance strategy to prevent relapses and preserve function over the course of their lives [3][4].

Measuring Progress Objectively

Because CIDP symptoms can fluctuate slightly from day to day, it is critical to use objective tools to track your progress rather than relying on memory alone [2]. Your doctor may use several validated scales:

  • I-RODS (Rasch-built Overall Disability Scale): A questionnaire that tracks your ability to perform daily activities, from buttoning clothes to running. It is highly sensitive to small but meaningful changes in your function [5][6].
  • INCAT (Inflammatory Neuropathy Cause and Treatment): A scale used to measure disability in your arms and legs [5].
  • Hand-Grip Dynamometry: A simple device you squeeze to measure your muscle strength in kilograms. This provides a clear “number” that can be tracked over months or years [7][8]. A drop of 4.5 kg or more is often seen as a sign that the disease may be becoming active again [9].

Reversible vs. Permanent Symptoms

One of the most important concepts in long-term CIDP is the difference between demyelination and axonal loss:

  • Demyelination (Reversible): When the immune system attacks the myelin “insulation,” the nerve signal slows down. This often causes weakness and numbness that can reverse once treatment stops the attack and the body repairs the insulation [10][11].
  • Axonal Loss (Permanent): If the attack is severe or left untreated for too long, the underlying nerve fiber (the axon) can be damaged or “die back.” Symptoms caused by axonal loss (like significant muscle wasting or permanent numbness) are much harder to reverse, even if the CIDP itself is now inactive [10][12].

This is why doctors emphasize “hitting hard and early”—the goal is to stop the attack before it moves from the reversible stage to the permanent stage [13].

Rebuilding Strength: Physical and Occupational Therapy

Medical treatments focus on stopping the immune attack, but they don’t rebuild muscle. A comprehensive care plan must include multidisciplinary support:

  • Physical Therapy (PT): Helps you safely rebuild strength and improve balance without over-fatiguing damaged nerves.
  • Occupational Therapy (OT): Teaches you new ways to perform daily tasks and recommends tools to make life easier.
  • Orthotics: Devices like Ankle-Foot Orthoses (AFOs) can help manage issues like ‘foot drop,’ significantly reducing your risk of falls and keeping you mobile while recovering.

The Path to Tapering

If you have been stable for a long period, you and your doctor may discuss tapering—a controlled trial of gradually reducing your medication to see if you still need the full dose [4].

  • The Goal: To find the lowest possible dose that keeps you stable, or to see if you have reached a state of natural remission [14][4].
  • The Safety Net: Tapering is done very slowly. If symptoms begin to return (a relapse), the dose is usually increased back to the previous successful level. Most patients who relapse during a taper quickly restabilize once the full dose is restored [4][15].

Living with CIDP means becoming an expert on your body. By tracking your scores and understanding your symptoms, you can work as a partner with your neurologist and therapy team to ensure you stay as strong and active as possible [2][16].

Common questions in this guide

How do doctors track my progress with CIDP?
Doctors use objective scales like the I-RODS questionnaire, INCAT scale, and hand-grip dynamometry. These tools measure your daily function and muscle strength over time to accurately track small but meaningful changes in your condition.
Can nerve damage from CIDP be reversed?
Weakness and numbness caused by demyelination can often be reversed once treatment stops the immune attack. However, if the underlying nerve fiber is damaged, known as axonal loss, the symptoms may become permanent.
What is the goal of tapering CIDP medication?
The goal of tapering is to find the lowest possible medication dose that keeps your symptoms stable, or to see if you have entered natural remission. Tapering is done very slowly under a doctor's supervision with a safety plan in place.
Do I need physical therapy for CIDP?
Yes, physical and occupational therapy are vital for rebuilding strength and improving balance safely. While medical treatments stop the immune attack, therapy helps you regain muscle function without over-fatiguing damaged nerves.
How can I manage foot drop caused by CIDP?
Orthotics like ankle-foot orthoses can help manage foot drop. These devices provide support, reduce the risk of tripping and falling, and help keep you safely mobile while you recover.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What objective scale (like INCAT or I-RODS) will we use to track my progress at our appointments?
  2. 2.How much of my current weakness is likely due to active inflammation (reversible) versus permanent axonal damage?
  3. 3.Are there specific physical or occupational therapists you recommend who understand neuromuscular diseases?
  4. 4.If we decide to try tapering my medication, what is the exact 'safety net' plan if my symptoms begin to return?
  5. 5.Would orthotics, like ankle-foot braces, help prevent me from falling or tripping while we wait for the medication to work?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

    Bus SRM, Broers MC, Lucke IM, et al.

    Journal of neurology 2022; (269(2)):945-955 doi:10.1007/s00415-021-10677-5.

    PMID: 34173873
  2. 2

    Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives.

    van Doorn IN, Eftimov F, Wieske L, et al.

    Therapeutics and clinical risk management 2024; (20()):111-126 doi:10.2147/TCRM.S360249.

    PMID: 38375075
  3. 3

    Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.

    Markvardsen LH, Sindrup SH, Christiansen I, et al.

    European journal of neurology 2017; (24(2)):412-418 doi:10.1111/ene.13218.

    PMID: 28000311
  4. 4

    Practical Approach to Managing SCIg Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

    Vu T, Guerra C, Suresh N, et al.

    Muscle & nerve 2026; (73(5)):765-771 doi:10.1002/mus.70151.

    PMID: 41589759
  5. 5

    Outcome measures in CIDP: A scoping and mapping review.

    Rajabally YA, Boggia GM, Riley D, et al.

    Journal of the neurological sciences 2025; (477()):123654 doi:10.1016/j.jns.2025.123654.

    PMID: 40839897
  6. 6

    Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.

    Vanhoutte EK, Draak TH, Gorson KC, et al.

    Journal of the peripheral nervous system : JPNS 2015; (20(3)):289-95 doi:10.1111/jns.12118.

    PMID: 26114893
  7. 7

    Validation of the Korean version of inflammatory Rasch-built Overall Disability Scale in patients with inflammatory neuropathy.

    Ju W, Min YG, Kim JS, et al.

    Journal of the peripheral nervous system : JPNS 2025; (30(1)):e12676 doi:10.1111/jns.12676.

    PMID: 39655711
  8. 8

    Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.

    Tsoumanis P, Chatzoglou T, Smyris TI, et al.

    Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.

    PMID: 40115839
  9. 9

    Minimal Clinically Important Difference for the Jamar Hand Grip Dynamometer in CIDP: A Korea-UK Study.

    Min YG, Rajabally Z, Ju W, et al.

    European journal of neurology 2025; (32(8)):e70335 doi:10.1111/ene.70335.

    PMID: 40853085
  10. 10

    Increased muscle echointensity correlates with clinical disability and muscle strength in chronic inflammatory demyelinating polyneuropathy.

    Fisse AL, Fiegert S, Stoykova Z, et al.

    European journal of neurology 2021; (28(5)):1698-1705 doi:10.1111/ene.14716.

    PMID: 33404183
  11. 11

    Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

    Oaklander AL, Lunn MP, Hughes RA, et al.

    The Cochrane database of systematic reviews 2017; (1()):CD010369 doi:10.1002/14651858.CD010369.pub2.

    PMID: 28084646
  12. 12

    [The clinical analysis of diabetic patients with chronic inflammatory demyelinating polyradiculoneuropathy].

    Sun QL, Sun AP, Fu Y, Fan DS

    Zhonghua nei ke za zhi 2018; (57(10)):749-752 doi:10.3760/cma.j.issn.0578-1426.2018.10.010.

    PMID: 30293336
  13. 13

    Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.

    Quint P, Schroeter CB, Kohle F, et al.

    Journal of neurology 2024; (271(9)):5930-5943 doi:10.1007/s00415-024-12548-1.

    PMID: 38990346
  14. 14

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  15. 15

    Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.

    Adrichem ME, Eftimov F, van Schaik IN

    Journal of the peripheral nervous system : JPNS 2016; (21(3)):121-7 doi:10.1111/jns.12176.

    PMID: 27241239
  16. 16

    Current clinical management of CIDP with immunoglobulins in France: An expert opinion.

    Cintas P, Bouhour F, Cauquil C, et al.

    Revue neurologique 2023; (179(8)):914-922 doi:10.1016/j.neurol.2023.03.010.

    PMID: 37019741

This page provides educational information on long-term CIDP management. Always consult your neurologist before modifying treatments or starting new physical therapy regimens.

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.